Tyvaso (treprostinil)
Also marketed as Remodulin and Orenitram and Tyvaso DPI. An approved treatment for Pulmonary Arterial Hypertension.
The same compound appears under different names depending on the context. Here is how to identify Treprostinil wherever you encounter it, plus the key facts at a glance.
- Generic name
- Treprostinil
- Brand names
- Tyvaso, Remodulin, Orenitram, Tyvaso DPI
- Drug class
- Prostacyclin analog
- Manufacturer
- United Therapeutics
- How it's taken
- Available as: IV continuous infusion (Remodulin, 2002), subcutaneous continuous infusion (Remodulin), inhaled nebulizer (Tyvaso, 2009), inhaled dry powder (Tyvaso DPI, 2022), and oral tablets (Orenitram, 2013).
A versatile prostacyclin analog available in four formulations (IV, subcutaneous, inhaled, and oral) for PAH. Relaxes narrowed pulmonary arteries and prevents blood clots, improving blood flow and exercise capacity.
The decision is expected in late April 2027. One email when it is public, with what it means in plain language, plus new trials for Idiopathic Pulmonary Fibrosis and FDA news. Unsubscribe anytime.
Where Treprostinil fits
Versatile prostacyclin available in subcutaneous, IV, inhaled, and oral formulations. The range of delivery options allows treatment across PAH severity levels.
How Treprostinil works
Treprostinil mimics prostacyclin, a natural substance that dilates blood vessels, prevents blood cell clumping, and inhibits abnormal smooth muscle growth. In PAH, the body doesn't produce enough prostacyclin, allowing arteries to constrict and remodel. Treprostinil supplements this deficiency across multiple pathways simultaneously.
Mechanism: Prostacyclin analog that dilates pulmonary blood vessels and inhibits platelet aggregation
Side effects and safety
Route-dependent: IV/SC can cause infusion site pain, headache, diarrhea, and jaw pain. Inhaled versions cause cough and throat irritation. Oral form causes headache, diarrhea, nausea, and flushing. Jaw pain is characteristic of prostacyclin therapy. When Remodulin is given through a central IV line, bloodstream infections and sepsis can occur and may be fatal, which is why under-the-skin infusion is the preferred route. Do not stop treprostinil suddenly or sharply lower the dose, because PAH symptoms can get worse. The label also warns about low blood pressure, a higher risk of bleeding, dose changes when drugs that affect the liver enzyme CYP2C8 are started or stopped, bronchospasm with the inhaled forms, and Orenitram tablets getting stuck in intestinal pouches (diverticula); Orenitram must not be used with severe liver impairment.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Treprostinil
Available as: IV continuous infusion (Remodulin, 2002), subcutaneous continuous infusion (Remodulin), inhaled nebulizer (Tyvaso, 2009), inhaled dry powder (Tyvaso DPI, 2022), and oral tablets (Orenitram, 2013). Route is chosen based on disease severity and patient preference.
Availability and cost
Generic versions may be available at a lower cost. Ask your pharmacist.
Prostacyclin analog available in multiple formulations (subcutaneous, IV, inhaled, and oral). Each delivery route has different pricing. Generic treprostinil injection is available for the infusion form, while the inhaled and oral forms are brand only.
Help paying for Tyvaso
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Copay help
Commercially insured patients may pay as little as $0 for Tyvaso, Tyvaso DPI, Remodulin or Orenitram, up to program maximums. Medicare, Medicaid, VA and TRICARE patients may not qualify.
For: private insurance · source - Free medicine program
Patient Assistance Program for eligible uninsured or underinsured US residents. Household income is checked through a third-party service; your doctor completes the enrollment form.
For: no insurance, underinsured · source - Insurance and case manager help
A Patient Navigator and Access & Affordability Specialists help with insurance coverage, prior authorizations and appeals, and set you up with a specialty pharmacy.
The official page does not say who qualifies. Ask the program. · source
Good to know: One program covers all four treprostinil products (Tyvaso, Tyvaso DPI, Remodulin, Orenitram). The Orenitram copay benefit has a monthly maximum; the others have an annual maximum. Some states restrict the copay program. Patients under 18 cannot register for the copay program.
- From a charity · HealthWell FoundationPulmonary Hypertension (Medicare Access) fundOpen
Pays for: Copays, premiums or other treatment costs. Medicare patients only.
- From a charity · TotalAssist (formerly PAN Foundation)Pulmonary Hypertension fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $9,500 per year. Requires health insurance (any kind).
- From a charity · The Assistance FundPulmonary Hypertension fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
The foundation says: “WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists a…”
Clinical trial results
Each formulation has independent clinical trial data. Inhaled treprostinil (Tyvaso) showed improvement in 6MWD on top of background oral therapy. INCREASE trial for PH-ILD showed landmark results for interstitial lung disease-associated PH.
Development history
First approved in 2002 as subcutaneous/IV infusion. United Therapeutics developed multiple formulations over two decades to improve convenience and tolerability. Tyvaso DPI (dry powder inhaler) approved 2022 as the most portable option.
Explore Pulmonary Arterial Hypertension trials
Other Pulmonary Arterial Hypertension treatments
Common questions about Treprostinil
▸What is Treprostinil (Tyvaso)?
A versatile prostacyclin analog available in four formulations (IV, subcutaneous, inhaled, and oral) for PAH. Relaxes narrowed pulmonary arteries and prevents blood clots, improving blood flow and exercise capacity.
▸How does Treprostinil work?
Treprostinil mimics prostacyclin, a natural substance that dilates blood vessels, prevents blood cell clumping, and inhibits abnormal smooth muscle growth. In PAH, the body doesn't produce enough prostacyclin, allowing arteries to constrict and remodel. Treprostinil supplements this deficiency across multiple pathways simultaneously.
▸What are the side effects of Treprostinil?
Route-dependent: IV/SC can cause infusion site pain, headache, diarrhea, and jaw pain. Inhaled versions cause cough and throat irritation. Oral form causes headache, diarrhea, nausea, and flushing. Jaw pain is characteristic of prostacyclin therapy. When Remodulin is given through a central IV line, bloodstream infections and sepsis can occur and may be fatal, which is why under-the-skin infusion is the preferred route. Do not stop treprostinil suddenly or sharply lower the dose, because PAH symptoms can get worse. The label also warns about low blood pressure, a higher risk of bleeding, dose changes when drugs that affect the liver enzyme CYP2C8 are started or stopped, bronchospasm with the inhaled forms, and Orenitram tablets getting stuck in intestinal pouches (diverticula); Orenitram must not be used with severe liver impairment.
▸How is Treprostinil taken?
Available as: IV continuous infusion (Remodulin, 2002), subcutaneous continuous infusion (Remodulin), inhaled nebulizer (Tyvaso, 2009), inhaled dry powder (Tyvaso DPI, 2022), and oral tablets (Orenitram, 2013). Route is chosen based on disease severity and patient preference.
▸Is Treprostinil FDA approved?
Yes, Treprostinil (Tyvaso) is FDA approved (2002) for the treatment of Pulmonary Arterial Hypertension.
▸What are the different ways to take treprostinil?
Treprostinil is available in four formulations: subcutaneous continuous infusion (Remodulin, via a small pump under the skin), intravenous continuous infusion (Remodulin, via central line), inhaled nebulizer (Tyvaso, 4 treatments daily), inhaled dry powder (Tyvaso DPI, a portable device), and oral extended-release tablets (Orenitram, taken 2-3 times daily). Your PAH specialist will recommend the best route based on your disease severity, lifestyle, and tolerability.
▸What causes the injection site pain with subcutaneous treprostinil?
Subcutaneous treprostinil infusion commonly causes significant pain, redness, and induration (hardening) at the infusion site. This is the most common reason patients discontinue subcutaneous Remodulin. The pain is caused by the drug's local tissue effects and can persist for days after a site change. Strategies to manage it include site rotation, topical anesthetics, ice packs, and gradual dose titration. Some patients tolerate it well while others find it unacceptable.
▸How does Tyvaso DPI compare to the Tyvaso nebulizer?
Both deliver treprostinil to the lungs but through different devices. The Tyvaso nebulizer uses a specialized ultrasonic device (TD-300) and requires liquid drug cassettes, taking several minutes per session. Tyvaso DPI is a compact dry-powder inhaler that delivers each dose in 1-2 breaths and is more portable. Both require 4 treatment sessions daily. Tyvaso DPI was approved in 2022 and offers greater convenience for active patients.
▸Is oral treprostinil as effective as the inhaled or infusion forms?
Oral treprostinil (Orenitram) generally achieves lower blood levels than the infusion or inhaled formulations, and the clinical trial results were more modest. It is typically used for patients with less severe PAH or as part of a transition strategy. The inhaled and infusion forms deliver higher drug concentrations to the pulmonary vasculature and are generally preferred for patients with more advanced disease.
▸Is treprostinil approved for lung disease-related pulmonary hypertension?
Yes. Inhaled treprostinil (Tyvaso) was approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) based on the landmark INCREASE trial. This was a major advance because few treatments had been shown to help PH caused by lung disease, which is distinct from PAH. The approval expanded treprostinil's use beyond PAH to a broader PH population.